In 1977, a group of scientists from The Prince of Songkla University initiated to investigate the possibility of isolating the biologically-active substances from mangosteen. This was the first mangosteen research based on international scientific standard, which involved cooperation from an interdisciplinary group of researchers.
June 2, 1988 – Natural Cosmetic Research Co.Ltd was founded by Professor Dr.Pichaet Wiriyajitra to manufacture beauty & cosmetic products from the research done on the Mangosteen and other natural plants extracts.
July 12, 2005 – Natural Cosmetic Research Co.Ltd changed its name to Asian Phytoceuticals Public Co., Ltd.
Nov 4, 2011 – Asian Phytoceuticals Public Co., Ltd (APCO) was listed on the Stock Exchange of Thailand (MAI)
APCO was awarded three prestigious awards by the Stock Exchange of Thailand: Best CEO Award, Best Company Performance Award and the Most Improved CSR Award.
June 24, 2015 - APCO was listed by Forbes magazine as Asia’s 200 Best under A Billion Company.
September 4, 2015 - The National Innovation Agency of Thailand (NIA) recognized the achievements of APCO cap as the innovative product of Thailand in improving the lives of people globally.
APCO was awarded three prestigious awards by the Stock Exchange of Thailand: Best Company Performance Award 2015 and Best CEO Award 2015.
The Stock Exchange of Thailand (SET) approved moving listed securities of APCO which has a registered capital of 300 million baht from the Market for Alternative Investment (MAI) to be traded on the Stock Exchange of Thailand (SET) and the trading of APCO listed securities on the SET begun on 14 May 2018. APCO common shares are now classified in the industry group of consumer products, personal products and pharmaceuticals sector.
The objectives of moving APCO listed securities to the SET are to expand the shareholder base, expand its market overseas, build confidence among consumers of APCO products, as well as to increase returns to shareholders.
APCO's business plan is to focus on promoting APCO products to gain acceptance in both Thailand and abroad. The company is currently studying the possibility of expanding its marketing channels and distribution of innovative products into overseas markets for HIV-infected and AIDS patients, for people infected with hepatitis B virus and for cancer patients.
BOARD OF DIRECTORS
||Chief Executive Officer||Board Director||Board Director|
Independent Director and
Independent Director and